In the same way, Ferrara et al. compared pre- and post-immunotherapy TGR in a retrospective cohort of 406 patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors, defining hyperprogressive disease as a RECIST progression at the first evaluation and a difference between on-treatment and pre-treatment TGR (∆TGR) exceeding 50% [18]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.